Latest:
Immunotherapy May Boost KRAS-Targeted Therapy in Pancreatic Cancer
A preclinical study offers a foundation for a combination strategy in future clinical trials for KRAS mutations.
Authors
University of Arizona Cancer Center
Latest:
$10.8M Initiative Unites Engineering and Health Researchers to Improve Cancer Treatments
A University of Arizona project, with funding from the state's New Economy Initiative, creates humanlike cancer models and growth environments to help improve prevention, diagnosis and treatment.
Daniel Boffa, MD
Daniel Boffa, MD, is a professor of thoracic surgery, division chief of Thoracic Surgery, and the clinical director of the Center for Thoracic Cancers at Yale School of Medicine.
Latest:
Dr Boffa on Factors Informing Early-Stage Esophageal Cancer Management
Daniel Boffa, MD, discusses the choice between definitive surgery vs definitive chemoradiotherapy for patients with early-stage esophageal carcinoma.
Sarah Sammons, MD
Latest:
Updated Efficacy of Mutant-Selective PI3Kα Inhibitor RLY-2608 in Combination With Fulvestrant in Patients With PIK3CA-Mutant HR+/HER2– Advanced Breast Cancer: ReDiscover Trial
Sarah Sammons, MD, presents updated results from the ReDiscover trial at the 2025 ASCO Annual Meeting in Chicago, demonstrating that the mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant shows promising clinical activity and a manageable safety profile in patients with PIK3CA-mutant HR+/HER2– advanced breast cancer.
Nerea Lopetegui-Lia, MD
Nerea Lopetegui-Lia, MD, is a breast medical oncologist and assistant professor at The Ohio State University Comprehensive Cancer Center—James
Latest:
Dr Lopetegui-Lia on Ongoing ADC Research in Metastatic TNBC
Nerea Lopetegui-Lia, MD, elaborates on several highly anticipated studies evaluating ADCs that could shape the future TNBC treatment paradigm.
Joseph Christopher Murray, MD, PhD
Joseph C. Murray, MD, PhD, is an assistant professor of Oncology, co-director of the Lung Cancer Precision Medicine Center of Excellence, and director of the Upper Aerodigestive Cancer Division Immunotherapy Database at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland.
Latest:
Dr Murray on the Safety of Encorafenib/Binimetinib and Dabrafenib/Trametinib in BRAF V600E+ NSCLC
Joseph C. Murray, MD, PhD, discusses the safety profiles of encorafenib/binimetinib and dabrafenib/trametinib in patients with BRAF V600E–mutant NSCLC.